Recruiting

Neoadjuvant Chemoradiotherapy Compared to Neoadjuvant Chemotherapy for Luminal-Type Locally Advanced Breast Cancer: A Clinical Study

This study focuses on preoperative treatment modalities for luminal-type locally advanced breast cancer. Based on modern precision radiotherapy technologies such as MRI-Linac, CyberKnife, and VMAT, it aims to compare the pCR rate, breast conserving surgery (BCS) rate, progression-free survival (PFS), and treatment-related side effects between preoperative neoadjuvant chemotherapy and preoperative neoadjuvant SBRT combined with chemotherapy in patients with this type of breast cancer. The goal is to provide new…

ClinicalTrials.gov IDNCT06697938

PhaseNA

Enrollment148

SponsorSichuan Cancer Hospital and Research Institute

Age18 Years

SexALL

I'm interested View official listing

Conditions studied

Breast Cancer

About this study

Interventions

Radiation: Preoperative SBRT for the Primary Lesion of Breast Cancer — SBRT for Primary Lesion of Breast Cancer, Radiation Dose: Primary Lesion ≤3 cm, GTV 24Gy/3F; Primary Lesion \>3 cm, GTV 30Gy/5F.

Primary outcomes

pCR (From enrollment to one month after surgery)

Eligibility information

Inclusion Criteria: 1. Pathologically confirmed invasive breast cancer ; 2. Breast MRI showing stages IIB to IIIC (2017 AJCC 8th edition staging); 3. Clinical staging confirmed by chest MRI and/or axillary ultrasound, as well as CT scans of the neck, abdomen, and pelvis, and bone scintigraphy, including T and N staging and assessment of distant metastasis; 4. Karnofsky performance score ≥80 or ECOG performance status of 0-1; 5. No history of allergies to doxorubicin, cyclophosphamide, paclitaxel/docetaxel; 6. No prior exposure to radiotherapy, chemotherapy, endocrine therapy, targeted therapy, or immunotherapy. Exclusion Criteria: 1. History of malignancy at other sites, excluding curable non-melanoma skin cancer and carcinoma in situ of the cervix; 2. Inability to complete MRI; 3. Inflammatory breast cancer; 4. Bilateral or multifocal primary tumors; 5. Active infection currently present; clinically evident heart disease; myocardial infarction or cerebrovascular accident within 6 months prior to enrollment.

Study locations

Sichuan Cancer Hospital, Chengdu, Sichuan 610041 China

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.